- Management TeamCo-Founder & Chief Executive Officer
Marc co-founded Minoryx in 2011 and since then has been taken the CEO role. He obtained a PhD in Chemistry from the University of Barcelona and has 15+ years of experience in drug discovery and development. Prior founding Minoryx, he worked at Crystax Pharmaceuticals and Oryzon Genomics where he managed several research projects and led the team in charge of target selection, structural biology, computational chemistry and hit ID through a fragment-based approach. At Oryzon, Marc actively contributed to the identification of the first-in-class inhibitors for the epigenetic target LSD1 currently in clinical studies. Marc is co-autor of several patents and publications and besides his activities in the technological field always had an entrepreneurial calling.Chief Medical OfficerUwe is a neurologist and psychiatrist. He received his medical degree as well as his doctorate in psychiatry from the University of Aachen (Germany). He is a member of the European College of Neuropsychopharmacology as well as the International Parkinson and Movement Disorder Society and is a founding member of the International College of Geriatric Psychoneuropharmacology.He has over 30 years of experience in pharmaceutical research and development, with a special focus on central nervous system (CNS) and particulary neurodegenerative disorders, having worked at Schering, Knoll, Novartis, F.Hoffmann-La Roche, Biotie Therapies, and Lupin. He has expertise in all aspects of drug development from first-in-man trials to regulatory filing.Chief Regulatory OfficerMaría is a regarded strategic regulatory expert with 20 years’ experience in regulatory affairs with an extensive track record of leading global registration activities for innovative new products. Prior to Minoryx, she was VP Regulatory Affairs and Quality at TiGenix bringing Alofisel from discovery to first allogenic stem cell product to receive EMA marketing authorization resulting in acquisition by Takeda. Board Member of EBE and member of EFPIA Regulatory Strategy Committee.Chaired regulatory working groups in various trade associations. Previous roles include, VP Regulatory Affairs and Quality at Cellerix, a stem cell therapy company on immune-based diseases. Holds a bachelor’s degree in Pharmacy and a Ph.D. in Immunology and worked in R&D at the Mayo Clinic, USA and the LUMC in the Netherlands.Director of BiologyPilar holds a PhD in Pharmacy from the Universitat de Barcelona. Supported by a Fulbright Postdoctoral Fellowship she worked at Harvard Medical School and later at Duke’s University, Durham (USA). Upon returning to Spain in 1995, she became an independent researcher at the Fundació Clínic- IDIBAPS in Barcelona and later on she moved to the pharmaceutical industry at Almirall as Head of the In Vivo Target Validation Unit in charge of generating and characterizing experimental models of diseases.She became program leader in Drug Discovery, supervising projects related to autoimmune diseases. During this period two drug candidates were forwarded to development and one of them has now entered in clinical trials. Afterwards she moved to CNIO as Head of In Vivo Target Validation from 2009 to 2012.Director of Clinical OperationsSílvia is a Pharmacist from the Universitat de Barcelona and after graduating she studied a Master of Science at King’s College, University of London. She has developed a broad experience in Clinical Development, pharmacovigilance and Regulatory Affairs at different companies such as GSK, Grifols and Almirall.In these companies, Sílvia managed several clinical research projects in different therapeutics indications, mainly in haematology, immunology, respiratory and dermatology. Some of these development programs obtained EMA and FDA approval to be marketed in both EU and US.Director of CMCMontse is a Chemist, MSc, from Institut Químic de Sarrià (Universitat Ramón Llull). She holds a PDD (Business Administration and Management, General) degree from IESE Business School-University of Navarra. She has developed a broad experience in CMC at different companies such as Combino-Medichem, Synthon and mAbxience.In these companies, Montse managed several development and operational projects in both drug substance and drug product areas, in small molecules and biosimilars. Some of the programs obtained approval in EU, US, Japan, Russia, Latam and were licensed out to be marketed worldwide.Director of Project ManagementXavier brings extensive experience in managing large and complex biotech projects in direct interaction with multidisciplinary teams in both the public sector and industry.He has managed portfolios of products through all phases of the project lifecycle (from idea to commercialization) serving as the business strategic coordinator between R&D, Regulatory Affairs, Manufacturing, QA/QC, Marketing and Logistics departments.Xavier holds a PhD in Biomedicine from the Universitat de Barcelona and he is also a certified Project Management Professional (PMP®) by the Project Management Institute (USA).Medical DirectorAdriana is a Medical Doctor from University of Rosario (Colombia), Clinical Pharmacologyst from Vall d’Hebron Hospital (Spain), with a MSc in Pharmaceutical Industry from University of Salamanca (Spain) and a PhD degree in Pharmacology from Autonomous University of Barcelona (Spain). She has more than 10 years of experience in clinical field and rich background in clinical research including clinical development for CNS indications from her previous positions along hospital setting, CRO (Pharmalex) and Industry (Insudpharma).